Hodgkin’s patients survive for longer but with more serious and lasting damage than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can [more]
Selected Reports by Janet Fricker Download full article
Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualised therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumour-associated macrophages as being [more]
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Hannah Brown Download full article
Results of a multicentre study show that a sequential high-dose chemotherapy variant of the standard treatment is safe and effective in relapsed Hodgkin’s patients. Download full article